Search Medical Condition
Please enter condition
Please choose location

Mulhouse, France Clinical Trials

A listing of Mulhouse, France clinical trials actively recruiting patients volunteers.

RESULTS

Found (48) clinical trials

Cohort of Patients With Rare Iron Overloads Excluding C282Y Homozygosity

Chronic iron overload are responsible for morbidity and mortality. There are many causes, genetic and acquired. Hepcidin deficiency related to genetic desease is one of them. This study concerns specifically this cause, and seeks to characterize these iron overloads on clinical, biological, genetic and functional point of view. A significant ...

Phase N/A

0.0 miles

Learn More »

Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung Cancer

Until recently, the first line treatment of metastatic Non Small Cell Lung Cancer (NSCLC) was a platine-based chemotherapy. It has been changed by the discovery of EGFR (Epidermal Growth Factor Receptor) mutations and associated treatment with Tyrosine Kinase Inhibitor (TKI) of EGFR. The superiority of EGFR TKI over chemotherapy for ...

Phase

0.0 miles

Learn More »

Abdominal Compartment Syndrome and Ruptured Aortic Aneurysm : Validation of a Predictive Test

Despite improved management techniques of ruptured abdominal aortic aneurysm, especially in vascular surgery, the mortality rate has not decreased these last years. The abdominal compartment syndrome (ACS) has been clearly identified as one of the main etiologies of mortality after ruptured aortic aneurysm. The mortality grow up with ACS in ...

Phase N/A

0.0 miles

Learn More »

Treat to Target Trial in Axial Spondylo Arthritis : The TICOSPA (Tight Control in Spondyloarthritis)

This study is reflecting the usual care either in accordance to the treating rheumatologist (arm: usual care) or in accordance to the international scientific recommendations (arm: T2T) The tight control means that as soon as a treatment is initiated in a patient, the time permitting to evaluate its potential efficacy/safety ...

Phase N/A

0.0 miles

Learn More »

Benefit of the Use of 3D Models and Tools in Hepatectomy Planning for Hepatocarcinomas

The detailed anatomical description of the liver described by Couinaud in 1954 is the basis for hepatic surgery. Surgical resection is the approach leading to the best survival rate in case of liver cancer. In hepatocarcinomas, systematic removal of the infected liver segment is considered the most effective technique to ...

Phase N/A

0.8 miles

Learn More »

A Study Of PF-05280586 (Rituximab-Pfizer) Or MabThera (Rituximab-EU) For The First-Line Treatment Of Patients With CD20-Positive Low Tumor Burden Follicular Lymphoma (REFLECTIONS B328-06)

This study will compare the safety and effectiveness of PF-05280586 versus rituximab-EU in patients with CD20-positive, low tumor burden follicular lymphoma. The primary hypothesis to be tested in this study is that the effectiveness of PF-05280586, as measured by the Overall Response Rate, is similar to that of rituximab-EU.

Phase

0.8 miles

Learn More »

Study of Carfilzomib Weekly Plus Melphalan and Prednisone in Untreated Symptomatic Elderly Multiple Myeloma

Overall design. This study is a Multicenter, Open-label, Phase 2 study of Carfilzomib Weekly +MP in Untreated Elderly MM. Eligible patients must have a symptomatic, untreated MM with a measurable disease. There is a dose escalation part in the study as the MTD remained to be determined for carfilzomib weekly ...

Phase

0.8 miles

Learn More »

Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma

Multiple myeloma (MM) is the second most common haematological malignancy (after non-Hodgkin's lymphoma), representing 1% of all cancers and 2% of all cancer deaths. Despite the increased efficacy of first-line agents, the majority of patients will eventually relapse and become resistant to all classes of available therapies. With over 15,000 ...

Phase

0.8 miles

Learn More »

Study of OSE2101 Versus Standard Treatment as 2nd or 3rd Line in HLA-A2 Positive Patients With Advanced NSCLC

The aim of this study is to demonstrate that OSE2101 (Arm A) is superior to standard chemotherapy, pemetrexed or docetaxel (Arm B), in prolonging overall survival (OS) in HLA-A2 positive patients with locally advanced (IIIB) or metastatic NSCLC as 2nd line therapy after failure of prior platinum-based chemotherapy or 3rd ...

Phase

0.8 miles

Learn More »